Alpha-1-microglobulin for use in the protection of kidneys in radionuclide therapy
AssigneeGuard Therapeutics International AB
InventorsBo Åkerström, Sven-Erik Strand, Magnus Göran Gram, Amanda Thuy Tran
Life of this patent
Estimating the term…
Abstract
This invention relates to α1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.
Claims11
A method of treating impaired glomerular filtration rate (GFR) kidney injury in a subject in need thereof undergoing radionuclide diagnostics (RD), radionuclide therapy (RNT), or radioimmunotherapy (RIT) comprising administering a compound labelled with a radionuclide, wherein the compound labelled with a radionuclide is a somatostatin analogue selected from the group consisting of octreotide, lanreotide, Tyr3-octreotide, Tyr3-octreotate, DOTADOC, DODATATE, DOTA-lanreotide, pasireotide, dopastatin, and octreotide LAR, said method further comprising administering α1-microglobulin (A1M) to said subject, wherein the A1M has at least 95% sequence identity with SEQ ID NO:
- 1 or SEQ ID NO:
- 2.
A kit comprising al A1M having at least 95% sequence identity with SEQ ID NO:
- 1 or SEQ ID NO:
- 2 and b) a diagnostic agent, a radionuclide therapeutic agent, or a radioimmunotherapeutic agent, said agent comprising a compound labelled with a radionuclide, wherein the compound labelled with a radionuclide is a somatostatin analogue selected from the group consisting of octreotide, lanreotide, Tyr3-octreotide, Tyr3-octreotate, DOTADOC, DODATATE, DOTA-lanreotide, pasireotide, dopastatin, and octreotide LAR.
Dependencies are inferred from the claim text.